This very high risk of double-hit CLL must now be confirmed (including the impact of TP53 mutation status and rare translocations involving MYC) for the targeted therapies (e.g. BTKi and BCL2 inhibitors) now used as first-line treatments. The gene discussed is MYC; the disease is B-cell chronic lymphocytic leukemia.